GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
14.70
-0.31 (-2.07%)
At close: Feb 13, 2026, 4:00 PM EST
14.50
-0.20 (-1.36%)
After-hours: Feb 13, 2026, 7:20 PM EST
GH Research Market Cap
GH Research has a market cap or net worth of $911.83 million as of February 13, 2026. Its market cap has increased by 80.86% in one year.
Market Cap
911.83M
Enterprise Value
618.53M
1-Year Change
80.86%
Ranking
Category
Stock Price
$14.70
Market Cap Chart
Since the IPO on June 25, 2021, GH Research's market cap has increased from $808.33M to $911.83M, an increase of 12.80%. That is a compound annual growth rate of 2.63%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 911.83M | 15.75% |
| Dec 31, 2025 | 787.76M | 116.30% |
| Dec 31, 2024 | 364.20M | 20.69% |
| Dec 29, 2023 | 301.75M | -40.32% |
| Dec 30, 2022 | 505.64M | -58.32% |
| Dec 31, 2021 | 1.21B | 50.07% |
| Jun 25, 2021 | 808.33M | - |
View and export this data all the way back to 2021. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Phathom Pharmaceuticals | 941.10M |
| UroGen Pharma | 940.86M |
| SpyGlass Pharma | 940.22M |
| Aktis Oncology | 932.80M |
| AbCellera Biologics | 927.94M |
| ArriVent BioPharma | 927.18M |
| Fortrea Holdings | 904.60M |
| BridgeBio Oncology Therapeutics | 901.47M |